| Title |
Intra-Articular Injections for the Treatment of Osteoarthritis
|
|---|---|
| Published in |
Drugs in R&D, November 2012
|
| DOI | 10.2165/11539760-000000000-00000 |
| Pubmed ID | |
| Authors |
Tommaso Iannitti, Daniele Lodi, Beniamino Palmieri |
| Abstract |
Osteoarthritis (OA), also called degenerative joint disease, is the most frequently occurring chronic musculoskeletal disease, particularly affecting the aging population. The use of viscosupplementation, i.e. intra-articular (IA) hyaluronic acid (HA) drug therapy, to treat OA, is growing worldwide, due to important results obtained from several clinical trials, which reported IA HA-related improvements in functional activity and pain management. This review is an update of the IA use of this compound in the treatment of OA, with clinical evidence from the last few years being discussed and used to delineate new trends for the future. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Peru | 1 | 25% |
| United States | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | <1% |
| Peru | 1 | <1% |
| Singapore | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 129 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 21 | 16% |
| Researcher | 15 | 11% |
| Other | 13 | 10% |
| Student > Ph. D. Student | 12 | 9% |
| Student > Postgraduate | 11 | 8% |
| Other | 26 | 20% |
| Unknown | 35 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 28% |
| Agricultural and Biological Sciences | 17 | 13% |
| Biochemistry, Genetics and Molecular Biology | 8 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Nursing and Health Professions | 5 | 4% |
| Other | 19 | 14% |
| Unknown | 40 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2022.
All research outputs
#4,698,517
of 23,275,636 outputs
Outputs from Drugs in R&D
#87
of 338 outputs
Outputs of similar age
#48,435
of 280,138 outputs
Outputs of similar age from Drugs in R&D
#11
of 32 outputs
Altmetric has tracked 23,275,636 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 338 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,138 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.